The 
Schizophrenics patients differ markedly in the dose of drug that they can tolerate. Some of this variation in the tolerance of the drug is attributable to factors such as individual metabolism, bioavailability, age and weight. Studies from Davis et al, 1989 showed that patients who received the same dose of the drug had large variations in the plasma levels. Therefore measuring plasma levels would provide information that could be useful to clin icians. Unfortunately this enthusiasm was diminished by a number of failures to provide reliable relationships between plasma levels and clinical response. Our new attempt using 19-Fluorine magnetic resonance spec troscopy to measure brain neuroleptic levels would, as we hope, give us more information (Bartels et al, 1986 (Bartels et al, , 1991 . Another problem is that each substance has a more or less large number of metabolites, partially active and partially inactive. Therefore a lot of research is needed to find solutions for these problems. Since haloperidol has only a single metabolite, which may not have significant antipsychotic activity.3 This indicates that measuring plasma from haloperidol concentration may useful for the clinician. Recently, a well-defined curvilinear relationship between plasma level and dopa min receptor occupancy based on positron emission tomographic studies has been reported by Farde et al and by Wolkin et al.4 At very low plasma levels of haloperidol, receptor blockade increased rapidly with small increases in the level. The increase in the blockade then tapered off at 5-15 ng/ml; above 20 ng/ml relatively little ad ditional increase in receptor blockade could be measured, even with marked increases in plasma levels. This is in remarkable agreement with clinical experience that there is little added benefit as plasma levels of haloperidol rise above 20 ng/ml (Baldessarini et al, 1988) , and a strong argument for the clinical merit of measuring plasma neuroleptic drug level. In Tuebingen we have begun, conducted by Prof. Gaertner with the systematic measuring of the plasma haloperidol levels to optimize the therapy of each patient. Between 10 and 25 percent of schizophrenic patients receive little benefit from typical neuroleptic drug therapy (Davis et al, 1980) . Though there are some strategies to treat this neuroleptic refractory population.
High dose treatment
One strategy is to set treatment-resistent patients on high dose therapy. A number of studies support the use of this regimen eg, Rifkin et al.13 However a study from Quitkin14 blindly compared two extremely different doses of fluphenazine (30 and 1200 mg! daily). The results favoured the standard dose above the "mega dose" treatment. Nevertheless in individual cases such treatment could be recommended, but side effects of the extrapyramidal system, especially the so called "neuroleptic malignant syndrome" most be ca refully 
Benzodiazepines
The literature on the use of benzodiazepines in treat ment refractory schizophrenia is divided, most reports have shown a lack of efficacy.22 However we could shown that some symptoms and some side effects, particularly akathisia was markedly reduced by combining lorazepam with neuroleptics. In our opinion anxious symptoms of schizophrenia and akathisia cannot be clearly seperated, therefore we prefer in such states a combined neuroleptic and benzodiazepine therapy (Bartels et al, 1987) Long Term Maintenance Strategies
It is well established that treating remitted schizo phrenic patients with neuroleptic drugs substantially lowers their rate of relapse. However, longterm main tenance therapy is associated with neurological side ef fects, the most serious problem beeing tardive dyskinesia. When drugs cannot be discontinued, the only strategy for reducing the risk of tardive dyskinesia was, before the availability of clozapine to treat patients with the lowest effective dose. With the availability of clozapine our strategy is to try set the patient on this compound when first signs of tardive dyskenesia arrise. We published a study, (Bartels, 1988) showing that even in serious cases there is a marked reduction of symptoms. We plan to replicate this results by using zothepine, a new compound from Japan, now introduced also in Germany, the trade name is Nipoleptr, also beeing free from extrapyramidal side effects. There are other reasons besides tardive dyskinisia for reducing the dosage neuroleptics in main tenance therapy. Extrapyramidal side effects, particu larly akathisia and akinesia worsen often the clinical condition of the patient. Akathisia is defined as the feeling of restlessness. In a study from Van Putten et al9 it was found that upto 60% of patients treated with a high-potency neuroleptic experienced some form of akathisia within seven days of starting the drug. Akinesia is a state which may be manifest in decreased spontaneous movement, diminished conversation and apathy. These symptoms show resemblance to the flattened affect and decreased motivation that characterize negative symp toms of schizophrenia. It is therefore understandable that they are frequently not well recognized. Concern about the above mentioned side effects lead to a search for methods for treating schizophrenic patients with the lowest effective dose. Currently two strategies are under active investigation. 
Clozapine
This drug is pharmacologically different from all of the available neuroleptics. Whereas conventional neuroleptics have strong affinity for the D2 dopamine receptors, clozapine has relatively weak affinity for D1 and D2 receptors. In addition to beeing a potent anticholernic agent, it has also significant blocking effects for 5HT2, alphal and histamine H1 receptors. The weak dopamine-blocking effect probably explains why clozapine produces only minimal elevation in serum prolactin, and why clozapine causes neglegible extrapyramidal side effects. Given these advantages of clozapine, it was hoped that the availability of the drug would represent a major innovation in the treatment of schizophrenia. However widespread use of clozapine in Europe revealed a high rate of agranulocytosis. This lead to a stop or a strong restriction in the clinical application of clozapine. Nevertheless this compound has been clinically available in Germany again since the 1980. Clinicians will be required to adhere an intensive monitoring system, including a weekly red and white blood cell count for first 18 weeks after starting the drug. Despite risk of agranulocytosis clozapine is an important drug for patient with a schizophrenic illness that is refractory to currently available drugs. delayed by some days (up to 7). This explain by the slow penetration rate of this compound in the brain. The second disadvantage is the marked rise in prolactin, originating from strong dopamine D2 blockade in the tubero-infundibular system. Extrapyramidal effects are extremely rare, though the substance is well tolerated by the patients. The same is the case with remoxipride, with the exception that this compound more rapidly passes blood brain barrier.
